In December 2025, Eli Lilly published the first positive Phase 3 readout for retatrutide (LY3437943), the triple-agonist peptide that had, until then, only been validated at Phase 2 scale
NYHA, New York Heart Association
319,321,322 These advancements have accelerated the shift from standard template chemistry to enhanced stability chemistry
Managing Side Effects Both weight loss medications can cause side effects like nausea, vomiting, and diarrhoea
Natural Products: Potential Source of DPP-IV Inhibitors. Current Protein & Peptide Science, vol
Semaglutide works by activating GLP-1 receptors in your brain and gut, which signals satiety and reduces appetitea mechanism backed by decades of clinical research showing sustained weight loss of 15-22% of body weight over 68 weeks